CliffBio
small molecule

IMCIVREE

SETMELANOTIDE ACETATE

Loss of exclusivityJuly 2034latest FDA-listed patent expiry
CompanyRhythm Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameIMCIVREE
Active ingredientSETMELANOTIDE ACETATE
StrengthEQ 10MG BASE/ML (EQ 10MG BASE/ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalNovember 2020
Marketing statusRX

Listed patents

PatentExpiresType
11129869July 2034product
8039435August 2032substance, product
9458195October 2027substance, product

Regulatory exclusivity

CodeExpires
ODE-508December 2031
ODE-509December 2031
ODE-402June 2029
I-987March 2029
NPPDecember 2027
ODE-336November 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

IMCIVREE patent cliff — loss of exclusivity July 2034 | CliffBio